Table 2.
Univariate analysis of predictors of reporting IVF-AO decline among respondents aged 35 and greater from 2015 through 2020
| Respondents declined: n (%) | Respondents not declined: n (%) | OR (95% CI) | |
|---|---|---|---|
| Total: 418 (4.8) | Total: 8242 (95.2) | ||
| Highest education level achieved* | |||
| GED or less | 8 (2.0) | 209 (2.5) | 0.64 (0.31–1.32) |
| Some college | 40 (9.6) | 1147 (13.9) | 0.57 (0.40–0.81) |
| College | 130 (32.1) | 3035 (36.9) | 0.72 (0.58–0.90) |
| Master’s or professional degree | 228 (56.3) | 3829 (46.6) | Reference |
| Income* | |||
| $0–$49K | 35 (9.6) | 468 (6.2) | 1.53 (1.02–2.30) |
| $50K–$99K | 102 (27.9) | 2288 (30.2) | 0.91 (0.68–1.23) |
| $100K–$199K | 147 (40.2) | 3137 (41.4) | 0.96 (0.73–1.26) |
| $200K+ | 82 (22.4) | 1678 (22.2) | Reference |
| Race/ethnicity | |||
| White | 199 (55.6) | 4100 (55.4) | Reference |
| Black or African American | 31 (8.7) | 493 (6.7) | 1.30 (0.88–1.90) |
| Latino | 33 (9.2) | 618 (8.4) | 1.10 (0.75–1.61) |
| Asian | 40 (11.2) | 743 (10.0) | 1.10 (0.78–1.57) |
| Other | 55 (15.4) | 1446 (19.5) | 0.78 (0.58–1.06) |
| Age (years)* | |||
| 35–37 | 74 (18.4) | 3199 (39.0) | Reference |
| 38–40 | 105 (26.0) | 2620 (32.0) | 1.73 (1.28–2.34) |
| 41–42 | 55 (13.7) | 1163 (14.2) | 2.04 (1.43–2.92) |
| 42+ | 169 (41.9) | 1213 (14.8) | 6.02 (4.55–8.00) |
| Self-reported diagnoses* | |||
| Anovulation | 216 (10.4) | 1868 (89.6) | 1.09 (0.66–1.79) |
| DOR | 46 (4.4) | 997 (95.6) | 3.65 (2.99–4.45)* |
| Endometriosis | 56 (3.1) | 1734 (96.9) | 0.90 (0.66–1.23) |
| Male | 28 (2.7) | 1005 (97.3) | 0.58 (0.44–0.77)* |
| PCOS | 156 (9.2) | 1545 (90.8) | 0.52 (0.35–0.76)* |
| Poor oocyte quality | 18 (2.2) | 785 (97.8) | 2.58 (2.10–3.17)* |
| Tubal blockage | 39 (5.0) | 738 (95.0) | 0.43 (0.27–0.69)* |
| Fibroid | 16 (7.6) | 195 (92.4) | 1.05 (0.75–1.47) |
| Immunologic | 40 (5.1) | 750 (94.9) | 1.64 (0.98–2.76) |
| RPL | 92 (3.3) | 2740 (96.7) | 1.06 (0.76–1.48) |
| Unexplained | 42 (6.0) | 653 (94.0) | 0.57 (0.45–0.72)* |
| State with mandated fertility coverage* | |||
| Yes | 267 (66.6) | 4819 (59.5) | Reference |
| No | 134 (33.4) | 3275 (40.5) | 0.74 (0.60–0.91) |
| Location | |||
| Northeast | 146 (37.0) | 2622 (32.7) | 1.21 (0.93–1.58) |
| Midwest | 57 (14.4) | 1233 (15.4) | 1.01 (0.72–1.41) |
| South | 96 (24.3) | 2089 (26.1) | Reference |
| West | 96 (24.3) | 2069 (25.8) | 1.01 (0.76–1.35) |
| Current practice type | |||
| Academic | 66 (16.4) | 1455 (17.7) | Reference |
| Private | 337 (83.4) | 6782 (82.3) | 1.10 (0.84–1.44) |
| Insurance coverage | |||
| None | 109 (31.8) | 2039 (30.2) | 1.08 (0.86–1.36) |
| Some fertility coverage (office, medication, testing, and/or procedures) | 234 (68.2) | 4723 (69.9) | Reference |
| Type of practice declining | |||
| Academic | 56 (19.5) | 1455 (17.7) | Reference0.89 (0.66–1.19) |
| Private | 231 (80.5) | 6782 (82.3) | |
| Both | 12 | N/A | |
| Missing | 85 | N/A | |
OR odds ratio modeled for reported decline of IVF-AO, CI confidence interval
*Significance with chi-square p value ≤ 0.05 level